Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)

E. Tremoli; G. Morazzoni; P. Maderna; S. Colli; R. Paoletti

doi:10.1016/0049-3848(81)90178-X

Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)

E. Tremoli, G. Morazzoni, P. Maderna, S. Colli, R. Paoletti

Centro Cardiologico Monzino

Research output: Contribution to journal › Article › peer-review

Abstract

Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.

Original language	English
Pages (from-to)	549-553
Number of pages	5
Journal	Thrombosis Research
Volume	23
Issue number	6
DOIs	https://doi.org/10.1016/0049-3848(81)90178-X
Publication status	Published - Sep 15 1981

Keywords

Experimental venous thrombosis
Thrombin inhibitors

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Hematology

Access to Document

10.1016/0049-3848(81)90178-X

Fingerprint Dive into the research topics of 'Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)'. Together they form a unique fingerprint.

Cite this

@article{57bba2b6d9db48fb837824156fc44d5f,

title = "Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)",

abstract = "Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.",

keywords = "Experimental venous thrombosis, Thrombin inhibitors",

author = "E. Tremoli and G. Morazzoni and P. Maderna and S. Colli and R. Paoletti",

year = "1981",

month = sep,

day = "15",

doi = "10.1016/0049-3848(81)90178-X",

language = "English",

volume = "23",

pages = "549--553",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451)

AU - Tremoli, E.

AU - Morazzoni, G.

AU - Maderna, P.

AU - Colli, S.

AU - Paoletti, R.

PY - 1981/9/15

Y1 - 1981/9/15

N2 - Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.

AB - Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.

KW - Experimental venous thrombosis

KW - Thrombin inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0019857586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019857586&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(81)90178-X

DO - 10.1016/0049-3848(81)90178-X

M3 - Article

C2 - 7324011

AN - SCOPUS:0019857586

VL - 23

SP - 549

EP - 553

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -